In a recent securities filing, Stryker Corporation, a global medical technology company based in Michigan, disclosed that an investigation launched by the Securities and Exchange Commission into possible violations of the Foreign Corrupt Practices Act (“FCPA”) was closed in December 2025. According to the Form 10-K, Stryker was informed by the SEC on December 16, 2025, that the Commission had ended its investigation into whether Stryker’s business operations in certain foreign countries violated the FCPA and other similar local laws. Stryker previously disclosed in a May 2025 securities filing that an FCPA inquiry initiated by the U.S. Department of Justice had been closed without further action.